论文部分内容阅读
目的 探讨 Ｍ Ｄ Ｒ１ 基因表达与原代细胞体外抗药性的关系，为原发上皮性卵巢癌合理化疗提供理论依据。方法 应用半定量逆转录———聚合酶链反应技术和 Ｍ Ｔ Ｔ 法体外药敏试验，检测了３７ 例原发上皮性卵巢癌原代细胞对临床常用抗癌药物的抗药性及其 Ｍ Ｄ Ｒ１基因表达情况。结果 原发上皮性卵巢癌 Ｍ Ｄ Ｒ１ 基因阳性表达率为３０ ％ 。 Ｍ Ｄ Ｒ１ 基因表达与 Ｍ Ｄ Ｒ 相关药物耐药有关，与非 Ｍ Ｄ Ｒ 相关药物耐药无关。结论 Ｍ Ｄ Ｒ１ 基因表达是原发上皮性卵巢癌抗 Ｍ Ｄ Ｒ 相关药物的主要原因。
Objective To investigate the relationship between the expression of M D R1 gene and the drug resistance of primary cells in vitro and to provide a theoretical basis for rational chemotherapy of primary epithelial ovarian cancer. Methods The semi-quantitative reverse transcription-polymerase chain reaction (MTP) and MTT assay in vitro were used to detect the resistance of 37 primary primary epithelial ovarian cancer cells to commonly used anticancer drugs and their MD R1 gene expression. Results The positive rate of M D R1 gene in primary epithelial ovarian cancer was 30%. M D R 1 gene expression and M D R related drug resistance related, and non-M D R related drug resistance has nothing to do. Conclusion M D R 1 gene expression is the main reason for anti-M D R-related drugs in primary epithelial ovarian cancer.